查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026787

杜普伊特倫攣縮症市場預測至2034年－按疾病類型、治療方法、診斷、給藥途徑、分銷管道、最終用戶和地區分類的全球分析

Dupuytren Disease Market Forecasts to 2034 - Global Analysis By Disease Type, Treatment, Diagnosis, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球杜普伊特倫氏症市場規模將達到 53 億美元，並在預測期內以 6.6% 的複合年成長率成長，到 2034 年將達到 89 億美元。

杜普伊特倫攣縮症（也稱為杜普伊特倫氏攣縮）是一種影響手部和手指的疾病。此病的特徵是手掌皮膚下的結締組織增厚和硬化。杜普伊特倫攣縮症的主要症狀是手掌上形成結節或腫塊，隨著病情發展，這些結節或腫塊會在組織中形成索狀結構，並將受影響的手指向內牽拉。

發病率增加

隨著全球人口老化，杜普伊特倫攣縮症患者人數自然增加，尤其是在高發生率地區。此外，人們對該疾病的認知不斷提高，診斷能力不斷進步，使得杜普伊特倫攣縮症病例的識別更加準確和快速。總體而言，杜普伊特倫攣縮症發病率的上升正在推動市場成長，因為它為改善患者照護和開發新治療方法創造了機會。

治療費用高昂

治療費用是杜普伊特倫攣縮症市場發展的重要限制因素，並影響市場需求。諸如切除術和筋膜切開術等外科手術以及某些藥物療法會產生大量費用，包括住院費、外科醫生費用和術後護理費。此外，由於杜普伊特倫攣縮症具有復發性，患者可能需要接受額外的治療，從而增加其長期總費用。

治療方法的技術創新

治療方法的技術創新是杜普伊特倫攣縮症市場發展的關鍵驅動力，推動了市場需求的成長。膠原蛋白酶注射療法的引入徹底改變了杜普伊特倫攣縮症的治療方式。膠原蛋白酶是一種能夠分解攣縮組織的酶，使受影響的手指能夠伸直。這種非手術療法無需切口和麻醉，為患者提供了一種創傷較小的治療選擇。

治療選擇有限

杜普伊特倫攣縮症在患者間表現出顯著的個體差異，包括疾病嚴重程度、受影響手指關節以及對治療的反應。這種差異使得預測治療結果和為每位患者選擇最佳治療方法變得困難。部分患者在治療後可能僅出現輕微改善或攣縮復發，可能需要額外的治療或合併治療方法。因此，杜普伊特倫攣縮症治療方法選擇的匱乏對市場成長構成了挑戰。

新冠疫情的影響

新冠疫情對杜普伊特倫攣縮症市場產生了重大影響，對患者照護和市場動態都帶來了挑戰。醫療系統優先應對疫情，導致常規醫療服務中斷，杜普伊特倫攣縮症的診斷和治療延誤。此外，疫情期間的供應鏈中斷和生產挑戰也影響了杜普伊特倫攣縮症特異性治療方法的供應和分銷。

在預測期內，放射線治療領域預計將佔據最大佔有率。

放射線治療預計將佔據最大的市場佔有率。放射線治療利用高能量輻射靶向並抑制與杜普伊特倫攣縮症相關的異常組織增生。這種非侵入性治療方法尤其適用於晚期患者，他們的手部功能已因攣縮和結節而受到影響。對於多指受累或手術後復發的病例，放射治療尤其有效。

在預測期內，腸外給藥領域預計將呈現最高的複合年成長率。

預計在預測期內，腸外給藥領域將顯著成長。在杜普伊特倫攣縮症的治療中，腸外給藥途徑發揮至關重要的作用，它將治療藥物直接輸送到患者體內，無需經過胃腸道。這種直接給藥方式確保藥物的快速吸收和分佈，從而達到最佳的疾病症狀控制效果。此外，腸外給藥途徑還能最大限度地降低藥物在胃腸道環境中分解和改變的風險，進而提高藥物的生物利用度。

市佔率最大的地區：

在預測期內，北美佔據了最大的市場佔有率。該地區擁有先進的醫療基礎設施、完善的法規結構，以及較高的杜普伊特倫攣縮症盛行率，尤其是在老年族群。該地區的醫療環境有利於採用先進的外科手術、注射療法和非侵入性治療方法。此外，研究機構、製藥公司和醫療服務提供者之間的合作也促進了該地區新型治療方法的研發。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現盈利成長。該地區在引進先進醫療技術和治療方法杜普伊特倫攣縮症方面取得了顯著進展。研究活動的活性化、區域和國際醫療機構之間的合作以及不斷改進的醫療政策，都促進了創新治療方法的開發和應用。經濟發展、醫療成本的降低以及對以患者為中心的醫療服務的日益重視，進一步推動了該地區的市場成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球杜普伊特倫攣縮症市場：依疾病類型分類

  • 一型
  • II 型
  • III型

第6章 全球杜普伊特倫攣縮症市場：依治療方式分類

  • 針刺筋膜切開術
  • 外科手術
  • 酵素注射
  • 放射線治療
  • 類固醇注射
  • 職業療法
  • 其他治療方法

第7章 全球杜普伊特倫攣縮症市場：依診斷分類

  • X光
  • 身體檢查
  • 其他診斷

第8章：全球杜普伊特倫攣縮症市場：依給藥途徑分類

  • 腸外
  • 口服
  • 其他給藥途徑

第9章：全球杜普伊特倫攣縮症市場：依分銷管道分類

  • 網路藥房
  • 零售藥房
  • 其他分銷管道

第10章 全球杜普伊特倫攣縮症市場：依最終用戶分類

  • 診所
  • 醫院
  • 學術研究機構

第11章 全球杜普伊特倫攣縮症市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Pfizer Inc
  • AstraZeneca
  • Endo International plc
  • LEO Pharma A/S
  • Spear Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Bristol-Meyers Squibb Company
  • Fresenius Kabi AG
  • GSK plc
  • Actiza Pharmaceutical Private Limited
  • Nantong Jinghua Pharmaceutical Co., Ltd
  • Novartis AG
  • Bayer AG.
  • Johnson & Johnson Services Ltd.
  • Aurobindo Pharma
Product Code: SMRC24742

According to Stratistics MRC, the Global Dupuytren Disease Market is accounted for $5.3 billion in 2026 and is expected to reach $8.9 billion by 2034 growing at a CAGR of 6.6% during the forecast period. Dupuytren's disease, also known as Dupuytren's contracture, is a medical condition that affects the hands and fingers. It is characterized by the thickening and tightening of the connective tissue beneath the skin in the palm of the hand. The primary feature of Dupuytren's disease is the development of nodules or lumps in the palm, which may progress to form cords of tissue that pull the affected fingers inward.

Market Dynamics:

Driver:

Increasing incidence

As the global population ages, particularly in regions with a higher prevalence of this condition, there is a natural rise in the number of individuals affected by Dupuytren's disease. Moreover, heightened awareness and improved diagnostic capabilities contribute to the more accurate and timely identification of Dupuytren's disease cases. Overall, the escalating incidence of Dupuytren's disease propels market growth by creating opportunities for improved patient care and the development of novel treatment modalities.

Restraint:

High cost of treatment

The cost of treatment serves as a notable restraint in the Dupuytren's disease market, impacting the demand. Surgical interventions, such as fasciectomy or fasciotomy, and certain pharmaceutical treatments involve substantial costs; include hospitalization, surgeon fees, and post-operative care. Moreover, the potential for recurrence in Dupuytren's disease necessitates additional treatments, amplifying the overall cost for patients over time.

Opportunity:

Technological innovations in treatment options

Technological innovations in treatment options are a significant driver in the Dupuytren disease market, accelerating the demand. The introduction of collagenase injections has revolutionized the treatment of Dupuytren disease. Collagenase is an enzyme that can break down the contracted tissue, enabling the straightening of the affected fingers. This non-surgical approach avoids the need for incisions or anaesthesia and provides patients with a less-invasive treatment option.

Threat:

Limited treatment options

Dupuytren disease exhibits significant heterogeneity among patients, with variations in disease severity, affected hand joints, and response to treatments. This variability makes it challenging to predict treatment outcomes and select the most appropriate intervention for each individual. Some patients may experience limited improvement or recurrence of contractures even after undergoing treatment, leading to the need for additional interventions or a combination of treatment approaches. Therefore, the limited treatment options in the dupuytren disease market pose a challenge to market growth.

Covid-19 Impact

The COVID-19 pandemic has significantly impacted the Dupuytren disease market, introducing challenges that have influenced both patient care and market dynamics. The healthcare system's prioritization of resources toward managing the pandemic has led to disruptions in routine medical services, delaying the diagnosis and treatment of Dupuytren disease. Additionally, supply chain disruptions and manufacturing challenges during the pandemic have affected the availability and distribution of Dupuytren-specific treatments.

The radiation therapy segment is expected to be the largest during the forecast period

The radiation therapy segment is estimated to hold the largest share. Radiation therapy involves the use of high-energy radiation to target and reduce abnormal tissue growth associated with Dupuytren's disease. This non-invasive treatment modality is particularly considered for individuals with advanced stages of the disease, characterized by contractures and nodules impacting hand function. It is especially beneficial in cases where multiple fingers are affected or when the disease recurs after surgery.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have lucrative growth during the forecast period. In Dupuytren's disease the parenteral route of administration plays a pivotal role in delivering therapeutic interventions directly into the patient's system, bypassing the gastrointestinal tract. This direct approach ensures rapid absorption and distribution of the therapeutic agent, allowing for optimal efficacy in managing the disease's symptoms. Moreover, the parenteral route minimizes the risk of degradation or alteration of the drug in the gastrointestinal environment, enhancing its bioavailability.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The region comprises advanced healthcare infrastructure, a well-established regulatory framework, and a high prevalence of Dupuytren's disease, particularly in the aging population. The region's healthcare landscape encourages the adoption of advanced surgical procedures, injectable treatments, and non-invasive options. Moreover, collaborations between research institutions, pharmaceutical companies, and healthcare providers contribute to the development of novel therapies in this region.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. In this region, there is a notable shift toward embracing advanced medical technologies and therapies for Dupuytren's disease. Increased research initiatives, collaborations between regional and international healthcare entities, and evolving healthcare policies contribute to the development and adoption of innovative treatment options. The market's growth in this region is further propelled by economic development, improved healthcare affordability, and a heightened focus on patient-centric care.

Key players in the market

Some of the key players in the Dupuytren Disease Market include Pfizer Inc, AstraZeneca, Endo International plc, LEO Pharma A/S, Spear Pharmaceuticals, Hikma Pharmaceuticals PLC, Bristol-Meyers Squibb Company, Fresenius Kabi AG, GSK plc, Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd, Novartis AG, Bayer AG., Johnson & Johnson Services Ltd. and Aurobindo Pharma.

Key Developments:

In August 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

Disease Types Covered:

  • Type I
  • Type II
  • Type III

Treatments Covered:

  • Needle Aponeurotomy
  • Surgery
  • Enzyme Injection
  • Radiation Therapy
  • Steroid Shot
  • Occupational Therapy
  • Other Treatments

Diagnosis Covered:

  • X-Ray
  • Physical Examination
  • Other Diagnosis

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Other Route of Administrations

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

End Users Covered:

  • Clinics
  • Hospitals
  • Academic & Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dupuytren Disease Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Type I
  • 5.3 Type II
  • 5.4 Type III

6 Global Dupuytren Disease Market, By Treatment

  • 6.1 Introduction
  • 6.2 Needle Aponeurotomy
  • 6.3 Surgery
  • 6.4 Enzyme Injection
  • 6.5 Radiation Therapy
  • 6.6 Steroid Shot
  • 6.7 Occupational Therapy
  • 6.8 Other Treatments

7 Global Dupuytren Disease Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 X-Ray
  • 7.3 Physical Examination
  • 7.4 Other Diagnosis

8 Global Dupuytren Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Oral
  • 8.4 Other Route Of Administrations

9 Global Dupuytren Disease Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy
  • 9.4 Other Distribution Channels

10 Global Dupuytren Disease Market, By End User

  • 10.1 Introduction
  • 10.2 Clinics
  • 10.3 Hospitals
  • 10.4 Academic & Research Institutes

11 Global Dupuytren Disease Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc
  • 13.2 AstraZeneca
  • 13.3 Endo International plc
  • 13.4 LEO Pharma A/S
  • 13.5 Spear Pharmaceuticals
  • 13.6 Hikma Pharmaceuticals PLC
  • 13.7 Bristol-Meyers Squibb Company
  • 13.8 Fresenius Kabi AG
  • 13.9 GSK plc
  • 13.10 Actiza Pharmaceutical Private Limited
  • 13.11 Nantong Jinghua Pharmaceutical Co., Ltd
  • 13.12 Novartis AG
  • 13.13 Bayer AG.
  • 13.14 Johnson & Johnson Services Ltd.
  • 13.15 Aurobindo Pharma

List of Tables

  • Table 1 Global Dupuytren Disease Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Dupuytren Disease Market Outlook, By Disease Type (2023-2034) ($MN)
  • Table 3 Global Dupuytren Disease Market Outlook, By Type I (2023-2034) ($MN)
  • Table 4 Global Dupuytren Disease Market Outlook, By Type II (2023-2034) ($MN)
  • Table 5 Global Dupuytren Disease Market Outlook, By Type III (2023-2034) ($MN)
  • Table 6 Global Dupuytren Disease Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 7 Global Dupuytren Disease Market Outlook, By Needle Aponeurotomy (2023-2034) ($MN)
  • Table 8 Global Dupuytren Disease Market Outlook, By Surgery (2023-2034) ($MN)
  • Table 9 Global Dupuytren Disease Market Outlook, By Enzyme Injection (2023-2034) ($MN)
  • Table 10 Global Dupuytren Disease Market Outlook, By Radiation Therapy (2023-2034) ($MN)
  • Table 11 Global Dupuytren Disease Market Outlook, By Steroid Shot (2023-2034) ($MN)
  • Table 12 Global Dupuytren Disease Market Outlook, By Occupational Therapy (2023-2034) ($MN)
  • Table 13 Global Dupuytren Disease Market Outlook, By Other Treatments (2023-2034) ($MN)
  • Table 14 Global Dupuytren Disease Market Outlook, By Diagnosis (2023-2034) ($MN)
  • Table 15 Global Dupuytren Disease Market Outlook, By X-Ray (2023-2034) ($MN)
  • Table 16 Global Dupuytren Disease Market Outlook, By Physical Examination (2023-2034) ($MN)
  • Table 17 Global Dupuytren Disease Market Outlook, By Other Diagnosis (2023-2034) ($MN)
  • Table 18 Global Dupuytren Disease Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 19 Global Dupuytren Disease Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 20 Global Dupuytren Disease Market Outlook, By Oral (2023-2034) ($MN)
  • Table 21 Global Dupuytren Disease Market Outlook, By Other Route Of Administrations (2023-2034) ($MN)
  • Table 22 Global Dupuytren Disease Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 23 Global Dupuytren Disease Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 24 Global Dupuytren Disease Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 25 Global Dupuytren Disease Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 26 Global Dupuytren Disease Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Dupuytren Disease Market Outlook, By Clinics (2023-2034) ($MN)
  • Table 28 Global Dupuytren Disease Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Dupuytren Disease Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.